Clinical trial
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in…
NCT00458523 · Leeds Cancer Centre at St. James's University Hospital, Other · Completed
Key facts
| NCT number | NCT00458523 |
|---|---|
| Title | Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission |
| Official title | Eradication of Minimal Residual Disease (MRD) in Patients With Chronic Lymphocytic Leukaemia (CLL) With Alemtuzumab: A Phase II Study |
| Lead sponsor | Leeds Cancer Centre at St. James's University Hospital, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Genetic, Other |
| Interventions | alemtuzumab, fluorescence in situ hybridization, mutation analysis, flow cytometry |
| Enrollment | 54 |
| Start date | Dec 1, 2006 |
| Completion | Feb 1, 2008 |
| First posted | Apr 11, 2007 |
| Last update posted | Aug 12, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: